# Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease

> **NCT07129642** · EARLY_PHASE1 · RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 5 (estimated)

## Conditions studied

- Graves Disease

## Interventions

- **BIOLOGICAL:** Allogeneic CAR-T

## Key facts

- **NCT ID:** NCT07129642
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-10
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07129642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07129642, "Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07129642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*